Tuesday, 6 April 2021

Ionis initiates Phase 3 trial of novel antisense medicine to treat leading cause of juvenile-onset ALS

Ionis initiates Phase 3 trial of novel antisense medicine to treat leading cause of juvenile-onset ALS admin Tue, 04/06/2021 - 16:03

source https://www.pharmatutor.org/pharma-news/2021/ionis-initiates-phase-3-trial-of-novel-antisense-medicine-to-treat-leading-cause-of-juvenile-onset-als
at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Pharma openings

  Opportunity for M.Pharm, Msc or PhD as Scientist at PGIMER M.Pharmacy or M.Sc 6 Year of Research Experience or PhD with 3 year of Experien...